
    
      PRIMARY OBJECTIVES:

      I. To assess the efficacy of the combination of ibrutinib and obinutuzumab in chemotherapy
      naive patients with indolent lymphomas.

      SECONDARY OBJECTIVES:

      I. To assess progression free survival rates and overall survival rates in indolent
      lymphomas.

      II. To assess safety and tolerability of the combination. III. To evaluate response using
      positron emission tomography (PET) and correlate PET negativity with durability of response.
    
  